6 Common Medications That May Reduce Dementia Risk

Common medications used to treat conditions such as hypertension, diabetes, and depression may also play a role in reducing the risk of developing dementia, according to a growing body of research highlighted in recent health reporting.

A review of multiple studies suggests that six widely prescribed drug classes — including certain blood pressure medications, diabetes treatments, and antidepressants — are associated with lower rates of cognitive decline in older adults. While these medications are not currently approved or prescribed specifically for dementia prevention, their observed effects on brain health have prompted increased scientific interest.

Blood Pressure and Diabetes Medications Show Promise

Among the most consistent findings involve antihypertensive drugs, particularly those targeting the renin-angiotensin system, such as ACE inhibitors and angiotensin receptor blockers (ARBs). Longitudinal studies have found that older adults who consistently use these medications exhibit slower rates of memory loss and lower incidence of Alzheimer’s disease compared to those with untreated hypertension.

Similarly, certain diabetes medications, especially metformin, have been linked to reduced dementia risk in observational research. Metformin, which improves insulin sensitivity and reduces inflammation, may help protect neurons from damage associated with aging and neurodegenerative processes. Some studies suggest that diabetic patients taking metformin have lower rates of cognitive decline than those using other glucose-lowering therapies, though researchers caution that confounding factors — such as overall health status and access to care — may influence these outcomes.

glucagon-like peptide-1 (GLP-1) receptor agonists, a newer class of diabetes and weight-loss drugs that includes medications like semaglutide and liraglutide, are under investigation for their potential neuroprotective effects. Early animal and human studies indicate these drugs may reduce brain inflammation and amyloid buildup, though definitive proof of dementia prevention in humans remains pending.

Antidepressants and Other Common Drugs Under Review

Selective serotonin reuptake inhibitors (SSRIs), commonly prescribed for depression and anxiety, have also appeared in studies examining dementia risk. Some longitudinal data suggest that long-term SSRI use may be associated with slower cognitive decline, possibly due to their effects on reducing chronic stress and inflammation, both of which are linked to neurodegeneration. However, other research has shown mixed results, with certain antidepressants potentially linked to higher risk in specific populations, underscoring the need for further study.

Statins, widely used to lower cholesterol, have produced inconsistent findings in dementia research. While some observational studies report a protective effect — particularly in individuals at high cardiovascular risk — randomized controlled trials have not consistently confirmed a benefit for cognitive outcomes. Experts note that statins may still support brain health indirectly by reducing stroke risk, a major contributor to vascular dementia.

Another medication drawing attention is low-dose aspirin, often used for heart disease prevention. Although aspirin’s anti-inflammatory and anti-clotting properties suggest a theoretical benefit for brain health, large-scale trials have not shown a clear reduction in dementia incidence with regular use. Some studies even raise concerns about bleeding risks in older adults, leading experts to advise against using aspirin solely for dementia prevention without medical guidance.

Correlation, Not Causation: Limits of Current Evidence

Despite promising associations, researchers emphasize that most existing data come from observational studies, which cannot prove that these medications directly prevent dementia. It remains possible that individuals who take these drugs differ in other ways — such as better access to healthcare, healthier lifestyles, or earlier diagnosis of chronic conditions — that independently reduce their dementia risk.

Randomized controlled trials, the gold standard for establishing causation, are limited in this area. Many trials were not designed to detect cognitive outcomes, and long-term follow-up is often lacking. Scientists urge caution in interpreting current findings and advise against prescribing these medications off-label for brain protection.

“We’re seeing intriguing signals across several drug classes,” said a neurologist specializing in aging and cognition, who requested not to be named pending ongoing research. “But we need more targeted trials to understand whether these effects are truly causal and which patients might benefit most.”

Ongoing Research and Future Directions

Several large-scale studies are currently underway to clarify these relationships. Trials investigating repurposed drugs like metformin and GLP-1 agonists for neurodegenerative diseases are expected to yield results in the coming years. Researchers are exploring whether combining medications with lifestyle interventions — such as exercise, diet, and cognitive training — could enhance protective effects.

For now, public health experts recommend focusing on proven strategies for dementia risk reduction: managing blood pressure and blood sugar, staying physically and mentally active, maintaining social engagement, and following a heart-healthy diet. Individuals should consult their healthcare providers before starting or stopping any medication based on cognitive health concerns.